0000000000383006

AUTHOR

Jan D. Schmitto

showing 2 related works from this author

Feasibility of Implantable Cardioverter Defibrillator Treatment in Five Patients With Familial Friedreich's Ataxia-A Case Series

2010

Friedreich's ataxia (FRA) is an autosomal recessive disease of the central nervous system that is associated with familial cardiomyopathy. Cardiac involvement is seen in more than 90% of the patients and is the most common cause of death in these patients. We present a case series and discuss the indications for implantable cardioverter defibrillator (ICD) implantation in FRA with review of the literature. Five pediatric patients who suffer from FRA (four female and one male, mean age 17.4 years) underwent ICD implantation between 2007 and 2008 in the University Hospital of Goettingen. The diagnosis of FRA was established by standard clinical criteria and proven in each case by genotyping a…

Tachycardiamedicine.medical_specialtyAtaxiamedicine.medical_treatmentBiomedical EngineeringCardiomyopathyMedicine (miscellaneous)Bioengineering030204 cardiovascular system & hematologySudden cardiac deathBiomaterialsAngina03 medical and health sciences0302 clinical medicineInternal medicinemedicine030212 general & internal medicinemedicine.diagnostic_testbusiness.industryRetrospective cohort studyGeneral MedicineImplantable cardioverter-defibrillatormedicine.disease3. Good healthCardiologymedicine.symptombusinessElectrocardiographyArtificial Organs
researchProduct

The clinical impact of donor-specific antibodies in heart transplantation.

2018

Donor-specific antibodies (DSA) are integral to the development of antibody-mediated rejection (AMR). Chronic AMR is associated with high mortality and an increased risk for cardiac allograft vasculopathy (CAV). Anti-donor HLA antibodies are present in 3-11% of patients at the time of heart transplantation (HTx), with de novo DSA (predominantly anti-HLA class II) developing post-transplant in 10-30% of patients. DSA are associated with lower graft and patient survival after HTx, with one study suggesting a three-fold increase in mortality in patients who develop de novo DSA (dnDSA). DSA against anti-HLA class II, notably DQ, are at particularly high risk for graft loss. Although detection o…

OncologyGraft Rejectionmedicine.medical_specialty2747 Transplantationmedicine.medical_treatment610 Medicine & health030204 cardiovascular system & hematology030230 surgeryAntibodies03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumans10220 Clinic for SurgeryImmunoadsorptionKidney transplantationHeart transplantationTransplantationbiologybusiness.industryHazard ratioImmunosuppressionmedicine.disease10020 Clinic for Cardiac Surgerybody regionsbiology.proteinHeart TransplantationRituximabPlasmapheresisAntibodybusinessmedicine.drugTransplantation reviews (Orlando, Fla.)
researchProduct